Research Article

Effect of ST2825 on the proliferation and apoptosis of human hepatocellular carcinoma cells

Published: March 04, 2016
Genet. Mol. Res. 15(1): gmr6826 DOI: https://doi.org/10.4238/gmr.15016826
Cite this Article:
(2016). Effect of ST2825 on the proliferation and apoptosis of human hepatocellular carcinoma cells. Genet. Mol. Res. 15(1): gmr6826. https://doi.org/10.4238/gmr.15016826
1,617 views

Abstract

The purpose of this study was to investigate the effect of ST2825, an inhibitor of myeloid differentiation factor 88 (MyD88), on the proliferation and apoptosis of human hepatocellular carcinoma (HCC) cells as well as the potential mechanism and clinical significance of ST2825 in the treatment of HCC. Immunohistochemical staining with an MyD88 antibody was performed on tissues from 80 human HCC patients and adjacent normal tissues. In the in vitro experiment, human HCC HepG-2 cells cultured in vitro were divided into the following groups: blank, control (1% DMSO), low-dose (2 μM), medium-dose (10 μM), and high-dose ST2825 (20 μM). Cell apoptosis was detected by the Annexin V-FITC assay, and HepG-2 cell proliferation was detected by the MTT assay. The expression of IκB, p65, cyclin D1, caspase-3, and bcl-2 in the cells after a 48-h treatment was assayed by western blot analysis. MyD88 expression in the HCC tissue was significantly higher than that in the adjacent normal tissue (P 0.05). Compared with the control, ST2825 significantly inhibited the proliferation of and promoted the apoptosis of HCC cells. Moreover, ST2825 significantly decreased bcl-2 expression, increased cleaved caspase-3 expression (P

The purpose of this study was to investigate the effect of ST2825, an inhibitor of myeloid differentiation factor 88 (MyD88), on the proliferation and apoptosis of human hepatocellular carcinoma (HCC) cells as well as the potential mechanism and clinical significance of ST2825 in the treatment of HCC. Immunohistochemical staining with an MyD88 antibody was performed on tissues from 80 human HCC patients and adjacent normal tissues. In the in vitro experiment, human HCC HepG-2 cells cultured in vitro were divided into the following groups: blank, control (1% DMSO), low-dose (2 μM), medium-dose (10 μM), and high-dose ST2825 (20 μM). Cell apoptosis was detected by the Annexin V-FITC assay, and HepG-2 cell proliferation was detected by the MTT assay. The expression of IκB, p65, cyclin D1, caspase-3, and bcl-2 in the cells after a 48-h treatment was assayed by western blot analysis. MyD88 expression in the HCC tissue was significantly higher than that in the adjacent normal tissue (P 0.05). Compared with the control, ST2825 significantly inhibited the proliferation of and promoted the apoptosis of HCC cells. Moreover, ST2825 significantly decreased bcl-2 expression, increased cleaved caspase-3 expression (P

About the Authors